Harmony Biosciences Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting net product revenue of $268.9 million for the third quarter and net income of $48.2 million.

Key Highlights

  • Net product revenue: $268,917 thousand for Q3 2026, up from $239,455 thousand in Q3 2025, according to the filing.
  • Net income: $48,196 thousand for the three months ended September 30, 2026, compared to $50,865 thousand in the same period of 2025.
  • Nine-month net income: $156,115 thousand for the nine months ended September 30, 2026, versus $136,201 thousand in the prior-year period.
  • Diluted earnings per share: $0.81 for Q3 2026 and $2.63 for the nine months ended September 30, 2026, as reported in the filing.
  • Total assets: $1,478,245 thousand as of September 30, 2026, up from $1,271,631 thousand at December 31, 2025.
  • Total stockholders' equity: $1,072,232 thousand at September 30, 2026, compared to $870,218 thousand at December 31, 2025.
  • Shares outstanding: 58,723,199 shares of common stock as of November 2, 2026, per the filing cover page.

Harmony Biosciences Reports Q3 2026 Financial Results

According to the Form 10-Q filed with the SEC for the quarterly period ended September 30, 2026, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported net product revenue of $268,917 thousand for the three months ended September 30, 2026, an increase from $239,455 thousand in the same quarter of 2025. For the nine months ended September 30, 2026, net product revenue totaled $745,584 thousand, compared to $624,677 thousand in the prior-year nine-month period.

The filing disclosed gross profit of $188,231 thousand for Q3 2026, compared to $179,805 thousand in Q3 2025. Total operating expenses for the quarter were $134,034 thousand, versus $114,318 thousand a year earlier, with research and development expenses rising to $71,663 thousand from $54,962 thousand. Operating income for the three months ended September 30, 2026 was $54,197 thousand, down from $65,487 thousand in Q3 2025. Net income for the quarter was $48,196 thousand, with diluted earnings per share of $0.81, compared to $50,865 thousand and $0.87 per diluted share in Q3 2025.

As of September 30, 2026, the company reported total assets of $1,478,245 thousand, including cash and cash equivalents of $647,099 thousand and short-term investments of $124,039 thousand. Long-term investments stood at $280,467 thousand. Total liabilities were $406,013 thousand, with long-term debt, net, at $129,104 thousand. Retained earnings grew to $317,018 thousand from $160,903 thousand at December 31, 2025, and total stockholders' equity reached $1,072,232 thousand. Stock-based compensation for the nine months ended September 30, 2026 was $28,001 thousand, as stated in the stockholders' equity table.

What Was Disclosed

Harmony Biosciences filed its quarterly report covering the period ended September 30, 2026, disclosing revenue growth, net income of $156,115 thousand for the nine-month period, expanded total assets of $1,478,245 thousand, and 58,723,199 shares of common stock outstanding as of November 2, 2026.